<DOC>
	<DOCNO>NCT00002905</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient HIV-related non-Hodgkin 's lymphoma relapse responded chemotherapy .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With HIV-Related Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate duration response etoposide , mitoxantrone , prednimustine patient relapse HIV-associated non-Hodgkin 's lymphoma ( NHL ) . II . Evaluate response rate duration response cyclophosphamide , doxorubicin , etoposide patient refractory HIV-associated NHL . III . Assess toxic effect regimens patient . OUTLINE : Patients relapse non-Hodgkin 's lymphoma ( NHL ) receive oral etoposide prednimustine day 1-5 intravenous mitoxantrone day 1 every 3 week . Patients refractory NHL receive cyclophosphamide , doxorubicin , etoposide continuous infusion 4 day every 4 week . All patient receive concomitant antiretroviral therapy zidovudine didanosine . G-CSF give hematologic support indicate . All patient evaluate response 2 course chemotherapy . Patients complete response ( CR ) receive 2 additional course . Patients stable partial response receive 2 additional course re-evaluated ; CR receive 2 course , stable partial response treat study physician 's discretion . Patients progressive disease remove study . PROJECTED ACCRUAL : 15-20 patient treat regimen .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednimustine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove nonHodgkin 's lymphoma first presentation No document CNS involvement ( i.e. , primary CNS meningeal lymphoma ) Positive serologic test HIV antibody require No opportunistic infection unless effectively treat Disease relapse , refractory , unresponsive firstline chemotherapy No 1 prior combination chemotherapy regimen Chemotherapy consist cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) CHOPlike regimen , ACVBP , similar regimen PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : At least 1 month Hematopoietic : Not specify Hepatic : Bilirubin le 5 time normal OR Transaminases le 5 time normal Renal : Creatinine le 2 mg/dL PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
</DOC>